Can we utilise the circadian clock to target cancer stem cells?

被引:0
|
作者
Lian, Jia-Wen [1 ]
Li, Shi-Yang [1 ]
Clarke, Robert B. [2 ]
Howell, Sacha J. [2 ]
Meng, Qing-Jun [1 ]
机构
[1] Univ Manchester, Manchester Acad Hlth Sci Ctr, Div Cell Matrix Biol & Regenerat Med, Fac Biol Med & Hlth,Sch Biol Sci, Manchester, England
[2] Univ Manchester, Fac Biol Med & Hlth, Div Canc Sci, Breast Biol Grp,Manchester Breast Ctr, Manchester, England
关键词
Circadian clock; Cancer stem cells; Metastasis; Drug resistance; Phenotypic plasticity; Circadian medicine; CASEIN KINASE-I; METASTATIC COLORECTAL-CANCER; GENE-EXPRESSION; BREAST-CANCER; SHIFT WORK; REV-ERB; PHOSPHORYLATION; IDENTIFICATION; TRANSCRIPTION; OSCILLATIONS;
D O I
10.1016/j.canlet.2024.217360
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The 24-hourly circadian clock has been implicated in the regulation of multiple cancer hallmarks and characteristics. Cancer stem cells (CSCs) are a small but significant population of cells within many cancers, characterised by their self-renewal and clonogenic capacities. Increasing evidence points to CSCs having prominent roles in metastasis and drug resistance. However, it remains largely unknown how circadian clocks are involved with CSCs and what implications these interactions have for cancer progression and therapeutics. In this review, we examine the growing evidence on the role of circadian clocks in CSCs and discuss the potential therapeutic implications. This opens up new opportunities to target CSCs through various chronotherapeutic approaches, potentially improving clinical cancer outcomes. We propose different scenarios in which targeting circadian clocks in CSCs or their surrounding microenvironment could be developed into effective therapeutic strategies, including: (1) direct pharmacological targeting of core clock molecules, (2) optimising the timing of systemic anticancer therapies, and (3) targeting the neighbouring cells or systemic factors that influence tumour cells in a circadian-dependent manner.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Cancer Stem Cells: How can we Target them?
    Ischenko, Ivan
    Seeliger, Hendrik
    Schaffer, Moshe
    Jauch, Karl-Walter
    Bruns, Christiane J.
    CURRENT MEDICINAL CHEMISTRY, 2008, 15 (30) : 3171 - 3184
  • [2] Circadian disruption in cancer and regulation of cancer stem cells by circadian clock An review
    Zhang, Yiling
    Zhang, Qiang
    Liu, Rundong
    Zhang, Dingxiao
    Hu, Guangyuan
    Chen, Xin
    CANCER LETTERS, 2025, 611
  • [3] Stem cells and the circadian clock
    Weger, Meltem
    Diotel, Nicolas
    Dorsemans, Anne-Claire
    Dickmeis, Thomas
    Weger, Benjamin D.
    DEVELOPMENTAL BIOLOGY, 2017, 431 (02) : 111 - 123
  • [4] Aspirin and new approaches for chemoprevention: can we target cancer stem cells?
    Paraskeva, Chris
    COLORECTAL CANCER, 2012, 1 (06) : 467 - 469
  • [5] Can we selectively target AML stem cells?
    Jordan, Craig T.
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2019, 32 (04)
  • [6] Can we finally target the leukemic stem cells?
    Jordan, Craig T.
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2008, 21 (04) : 615 - 620
  • [7] Potential Role of the Circadian Clock in the Regulation of Cancer Stem Cells and Cancer Therapy
    Lee, Yool
    Tanggono, Alfian Shan
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (22)
  • [8] Cancer stem cells: Are we missing the target?
    Jones, RJ
    Matsui, WH
    Smith, BD
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (08): : 583 - 585
  • [9] Clocking cancer: the circadian clock as a target in cancer therapy
    Francesca Battaglin
    Priscilla Chan
    Yuanzhong Pan
    Shivani Soni
    Meng Qu
    Erin R. Spiller
    Sofi Castanon
    Evanthia T. Roussos Torres
    Shannon M. Mumenthaler
    Steve A. Kay
    Heinz-Josef Lenz
    Oncogene, 2021, 40 : 3187 - 3200
  • [10] Clocking cancer: the circadian clock as a target in cancer therapy
    Battaglin, Francesca
    Chan, Priscilla
    Pan, Yuanzhong
    Soni, Shivani
    Qu, Meng
    Spiller, Erin R.
    Castanon, Sofi
    Torres, Evanthia T. Roussos
    Mumenthaler, Shannon M.
    Kay, Steve A.
    Lenz, Heinz-Josef
    ONCOGENE, 2021, 40 (18) : 3187 - 3200